Quantcast

Latest Herceptin Stories

2008-12-12 17:10:00

EAST HANOVER, N.J., Dec. 12 /PRNewswire/ -- New data from two early clinical studies show that RAD001(R) (everolimus) may overcome resistance to Herceptin(R) (trastuzumab)* in women with HER2-positive metastatic breast cancer. These results support the initiation of a Phase III clinical trial program to fully explore the potential of RAD001 (proposed brand name Afinitor(R)) in breast cancer. Two Phase I studies were presented today during the CTRC-AACR San Antonio Breast Cancer...

2008-11-11 09:00:47

Monogram Biosciences, Inc. (Nasdaq:MGRM) today announced that additional EGFR/HER assays have been successfully tested in sets of fixed human tumors and are now available for use in drug development programs. These assays provide quantitative measurements of the HER2:HER3 heterodimer, and its associated downstream HER3:PI3K complex. An assay for p95, a truncated form of HER2, is in advanced development. These assays provide a measure of the activation state of key signaling pathways in tumors...

2008-10-13 06:00:18

By Liz Szabo Barbara Bradfield has lived to see dramatic changes in breast cancer. When she was diagnosed in 1989, Bradfield's tumor -- which produced an overabundance of a protein called HER2 -- was considered especially deadly. Today, women with tumors like hers have some of the best survival rates in breast cancer. Experts say the drug that has kept Bradfield healthy for so long, Herceptin, has changed the nature of breast cancer and helped doctors better understand what causes...

2008-10-12 15:00:21

By EATON, Dan National has been forced to trim its election health pledges due to tough economic times. Policies shed include a costly $40 million insurance rebate for seniors, while questions remain about the fate of funding plans for breast cancer drug Herceptin and Plunketline. On the campaign trail yesterday at a Palmerston North medical centre, National leader John Key unveiled plans to fund 20 new elective surgery theatres and train 800 additional surgeons, anaesthetists and...

2008-10-04 18:00:06

SUCCESSFUL businesswoman Jacqueline Williams was getting ready for a trip to London and taking her normal morning shower before setting off. But that journey never took place. Instead it was the start of a far more harrowing journey that continues to this very day. For while she was in the bathroom Jacqueline discovered a lump in her breast and with the alarm bells ringing her next stop was a visit to her GP. A couple of hospital appointments followed and tests were taken before she...

2008-09-23 18:00:13

By Madeleine Brindley Health Editor A HOSPITAL'S Saturday clinics for women with breast cancer are proving a great success. The innovative clinic at Velindre Cancer Centre has helped to boost capacity at the Cardiff hospital and reduce waiting times for patients. It was developed for women with breast cancer after the anti- cancer drug Herceptin was approved for use on the NHS. Cathy Barker, the integrated services manager and lead nurse at Velindre NHS Trust who pioneered the...

2008-09-23 09:00:15

SOUTH SAN FRANCISCO, Calif., Sept. 23 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. announced today that it has initiated a study, in collaboration with the Dana-Farber Cancer Institute (DFCI), to evaluate Monogram's HERmark(TM) Breast Cancer Assay in metastatic breast cancer. In the study, Monogram's proprietary HERmark assay will be used to analyze approximately 600 tissue samples from patients with breast cancer, approximately half of whom were eligible for treatment with...

2008-09-22 18:00:00

By Madeleine Brindley PATIENTS are receiving anti-cancer treatments at a special Saturday clinic in a Welsh hospital. Velindre Cancer Centre's weekend clinic has helped to boost capacity at the Cardiff hospital and reduce waiting times for patients. Developed especially for women with breast cancer to receive Herceptin and other cancer drugs, the service could be extended to Sunday opening in the future or relocated closer to patients' homes. Cathy Barker, the integrated services...

2008-09-15 18:00:37

Invitrogen Corporation, (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, has signed an exclusive U.S. distribution agreement with Biocare Medical LLC, a leading provider of immunohistochemistry reagents, multiplex stains, and automated platforms for the anatomic pathology market, for the new SPOT-Light(R) HER2 CISH Kit. The kit received U.S. Food and Drug Administration premarket approval in July, (click here for release), as an aid in...

2008-09-05 12:00:40

Sarah Cannon Research Institute (SCRI) investigators have found that "smart bomb" therapies are effective in treating breast cancer patients while minimizing side effects. Howard A. Burris III, M.D., SCRI's chief medical officer, is presenting interim Phase II clinical trial results of a drug named Trastuzumab-DM1 (T-DM1), a novel antibody drug conjugate, at noon today at the American Society of Clinical Oncology's Breast Cancer Symposium in Washington, D.C. T-DM1 is built from the...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related